Bevacizumab Biosimilar Market Overview

Ajouter une nouvelle offre d'emploi Health

2026-06-22 10:07:16 -

The Bevacizumab Biosimilar Market was valued at $2.18 billion in 2024 and is projected to reach $5 billion by 2035, growing at a CAGR of 7.8%. Bevacizumab biosimilars offer cost-effective alternatives to the reference biologic Avastin, treating multiple cancers by inhibiting vascular endothelial growth factor (VEGF). The market encompasses various formulation types including intravenous and...

0 Commentaires 0 Parts 12 Vue 0 Aperçu